Albumin Paclitaxel Combined with Intrapleural Infusion of Bevacizumab + Lobaplatin for the Second-Line Treatment of Patients with Non-Squamous Non-Small Cell Lung Cancer

Table 5

Univariate analysis of factors affecting the prognosis of patients in the treatment group.

Characters	PFS (months)	95% CI		OS (months)	95% CI
VEGF expression			<0.001			<0.001
High	4.901	4.712–5.090		12.309	11.615–13.002
Low	7.146	6.483–7.809		16.749	16.450–17.048
Liquor pleurae pH			<0.001			<0.001
＜7.35	5.071	4.678–5.463		13.022	12.623–13.420
≥7.35	6.678	6.237–7.119		17.054	16.748–17.361
Hydrothorax CD4+/CD8+ value			0.002			<0.001
High	6.594	6.324–6.864		16.349	15.886–16.833
Low	5.788	5.307–6.268		11.884	11.592–12.176